| GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca | Ben Fidler | 12/03/18 | Boston |
| Heron Gains FDA Support For Nausea Drug After A Year Under Review | David Holley | 08/10/16 | San Francisco |
| East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More | Ben Fidler | 09/04/15 | Boston |
| East Coast Biotech Roundup: Maraganore, Flex, NPS, Retrophin, & More | Ben Fidler | 09/15/14 | Boston |
| East Coast Biotech Roundup: LTI, SolveBio, Proteon, & More | Ben Fidler | 05/16/14 | Boston |
| Tesaro Climbs on Phase 3 Data for Nausea Drug | Ben Fidler | 05/12/14 | Boston |
| East Coast Biotech Roundup: Scholar Rock, Dicerna, Eleven, & More | Ben Fidler | 01/03/14 | Boston |
| Investors Sink Tesaro Shares on Phase 3 Misses For Cancer Drug | Ben Fidler | 12/23/13 | Boston |
